Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 187

1.

Tumor-Targeted Drug Conjugates as an Emerging Novel Therapeutic Approach in Small Cell Lung Cancer (SCLC).

Deneka AY, Boumber Y, Beck T, Golemis EA.

Cancers (Basel). 2019 Sep 3;11(9). pii: E1297. doi: 10.3390/cancers11091297. Review.

2.

Comprehensive characterization of RAS mutations in colon and rectal cancers in old and young patients.

Serebriiskii IG, Connelly C, Frampton G, Newberg J, Cooke M, Miller V, Ali S, Ross JS, Handorf E, Arora S, Lieu C, Golemis EA, Meyer JE.

Nat Commun. 2019 Aug 19;10(1):3722. doi: 10.1038/s41467-019-11530-0.

3.

Combined inhibition of Aurora A and p21-activated kinase 1 as a new treatment strategy in breast cancer.

Korobeynikov V, Borakove M, Feng Y, Wuest WM, Koval AB, Nikonova AS, Serebriiskii I, Chernoff J, Borges VF, Golemis EA, Shagisultanova E.

Breast Cancer Res Treat. 2019 Sep;177(2):369-382. doi: 10.1007/s10549-019-05329-2. Epub 2019 Jun 28.

4.

Comprehensive Genomic Landscapes in Early and Later Onset Colorectal Cancer.

Lieu CH, Golemis EA, Serebriiskii IG, Newberg J, Hemmerich A, Connelly C, Messersmith WA, Eng C, Eckhardt SG, Frampton G, Cooke M, Meyer JE.

Clin Cancer Res. 2019 Jun 26. doi: 10.1158/1078-0432.CCR-19-0899. [Epub ahead of print]

PMID:
31243121
5.

An improved method of delivering a sclerosing agent for the treatment of malignant pleural effusion.

Beck TN, Deneka AY, Chai L, Kanach C, Johal P, Alvarez NJ, Boumber Y, Golemis EA, Laub GW.

BMC Cancer. 2019 Jun 24;19(1):614. doi: 10.1186/s12885-019-5777-z.

6.

Disease-Associated Genetic Variation in Human Mitochondrial Protein Import.

Nicolas E, Tricarico R, Savage M, Golemis EA, Hall MJ.

Am J Hum Genet. 2019 May 2;104(5):784-801. doi: 10.1016/j.ajhg.2019.03.019. Review.

PMID:
31051112
7.

Unexpected Activities in Regulating Ciliation Contribute to Off-target Effects of Targeted Drugs.

Kiseleva AA, Korobeynikov VA, Nikonova AS, Zhang P, Makhov P, Deneka AY, Einarson MB, Serebriiskii IG, Liu H, Peterson JR, Golemis EA.

Clin Cancer Res. 2019 Jul 1;25(13):4179-4193. doi: 10.1158/1078-0432.CCR-18-3535. Epub 2019 Mar 13.

PMID:
30867219
8.

Microscopy-Based Automated Live Cell Screening for Small Molecules That Affect Ciliation.

Zhang P, Kiseleva AA, Korobeynikov V, Liu H, Einarson MB, Golemis EA.

Front Genet. 2019 Feb 12;10:75. doi: 10.3389/fgene.2019.00075. eCollection 2019.

9.

Combined Aurora Kinase A (AURKA) and WEE1 Inhibition Demonstrates Synergistic Antitumor Effect in Squamous Cell Carcinoma of the Head and Neck.

Lee JW, Parameswaran J, Sandoval-Schaefer T, Eoh KJ, Yang DH, Zhu F, Mehra R, Sharma R, Gaffney SG, Perry EB, Townsend JP, Serebriiskii IG, Golemis EA, Issaeva N, Yarbrough WG, Koo JS, Burtness B.

Clin Cancer Res. 2019 Jun 1;25(11):3430-3442. doi: 10.1158/1078-0432.CCR-18-0440. Epub 2019 Feb 12.

10.

Interaction of germline variants in a family with a history of early-onset clear cell renal cell carcinoma.

Nicolas E, Demidova EV, Iqbal W, Serebriiskii IG, Vlasenkova R, Ghatalia P, Zhou Y, Rainey K, Forman AF, Dunbrack RL Jr, Golemis EA, Hall MJ, Daly MB, Arora S.

Mol Genet Genomic Med. 2019 Mar;7(3):e556. doi: 10.1002/mgg3.556. Epub 2019 Jan 24.

11.

Molecular mechanisms of the preventable causes of cancer in the United States.

Golemis EA, Scheet P, Beck TN, Scolnick EM, Hunter DJ, Hawk E, Hopkins N.

Genes Dev. 2018 Jul 1;32(13-14):868-902. doi: 10.1101/gad.314849.118. Epub 2018 Jun 26. Review.

12.

Ciliary signalling in cancer.

Liu H, Kiseleva AA, Golemis EA.

Nat Rev Cancer. 2018 Aug;18(8):511-524. doi: 10.1038/s41568-018-0023-6. Review.

13.

NEDD9 promotes oncogenic signaling, a stem/mesenchymal gene signature, and aggressive ovarian cancer growth in mice.

Gabbasov R, Xiao F, Howe CG, Bickel LE, O'Brien SW, Benrubi D, Do TV, Zhou Y, Nicolas E, Cai KQ, Litwin S, Seo S, Golemis EA, Connolly DC.

Oncogene. 2018 Aug;37(35):4854-4870. doi: 10.1038/s41388-018-0296-y. Epub 2018 May 18.

14.

Ganetespib limits ciliation and cystogenesis in autosomal-dominant polycystic kidney disease (ADPKD).

Nikonova AS, Deneka AY, Kiseleva AA, Korobeynikov V, Gaponova A, Serebriiskii IG, Kopp MC, Hensley HH, Seeger-Nukpezah TN, Somlo S, Proia DA, Golemis EA.

FASEB J. 2018 May;32(5):2735-2746. doi: 10.1096/fj.201700909R. Epub 2018 Jan 10.

15.

RNA Interference Screening to Identify Proliferation Determinants in Breast Cancer Cells.

Zhang YW, Nasto RE, Jablonski SA, Serebriiskii IG, Surana R, Murray J, Johnson M, Riggins RB, Clarke R, Golemis EA, Weiner LM.

Bio Protoc. 2017;7(15). pii: e2435. doi: 10.21769/BioProtoc.2435. Epub 2017 Aug 5.

16.

NSD1- and NSD2-damaging mutations define a subset of laryngeal tumors with favorable prognosis.

Peri S, Izumchenko E, Schubert AD, Slifker MJ, Ruth K, Serebriiskii IG, Guo T, Burtness BA, Mehra R, Ross EA, Sidransky D, Golemis EA.

Nat Commun. 2017 Nov 24;8(1):1772. doi: 10.1038/s41467-017-01877-7.

17.

Functional analysis of rare variants in mismatch repair proteins augments results from computation-based predictive methods.

Arora S, Huwe PJ, Sikder R, Shah M, Browne AJ, Lesh R, Nicolas E, Deshpande S, Hall MJ, Dunbrack RL Jr, Golemis EA.

Cancer Biol Ther. 2017 Jul 3;18(7):519-533. doi: 10.1080/15384047.2017.1326439. Epub 2017 May 11.

18.

Tumor-targeted SN38 inhibits growth of early stage non-small cell lung cancer (NSCLC) in a KRas/p53 transgenic mouse model.

Deneka AY, Haber L, Kopp MC, Gaponova AV, Nikonova AS, Golemis EA.

PLoS One. 2017 Apr 28;12(4):e0176747. doi: 10.1371/journal.pone.0176747. eCollection 2017.

19.

Mechanisms for nonmitotic activation of Aurora-A at cilia.

Korobeynikov V, Deneka AY, Golemis EA.

Biochem Soc Trans. 2017 Feb 8;45(1):37-49. doi: 10.1042/BST20160142. Review.

20.

Musashi RNA-Binding Proteins as Cancer Drivers and Novel Therapeutic Targets.

Kudinov AE, Karanicolas J, Golemis EA, Boumber Y.

Clin Cancer Res. 2017 May 1;23(9):2143-2153. doi: 10.1158/1078-0432.CCR-16-2728. Epub 2017 Jan 31. Review.

21.

Matrix-regulated integrin αvβ5 maintains α5β1-dependent desmoplastic traits prognostic of neoplastic recurrence.

Franco-Barraza J, Francescone R, Luong T, Shah N, Madhani R, Cukierman G, Dulaimi E, Devarajan K, Egleston BL, Nicolas E, Katherine Alpaugh R, Malik R, Uzzo RG, Hoffman JP, Golemis EA, Cukierman E.

Elife. 2017 Jan 31;6. pii: e20600. doi: 10.7554/eLife.20600.

22.

Identification of evolutionarily conserved DNA damage response genes that alter sensitivity to cisplatin.

Gaponova AV, Deneka AY, Beck TN, Liu H, Andrianov G, Nikonova AS, Nicolas E, Einarson MB, Golemis EA, Serebriiskii IG.

Oncotarget. 2017 Mar 21;8(12):19156-19171. doi: 10.18632/oncotarget.13353.

23.

Head and neck squamous cell carcinoma: Ambiguous human papillomavirus status, elevated p16, and deleted retinoblastoma 1.

Beck TN, Smith CH, Flieder DB, Galloway TJ, Ridge JA, Golemis EA, Mehra R.

Head Neck. 2017 Mar;39(3):E34-E39. doi: 10.1002/hed.24604. Epub 2016 Nov 8. Review.

24.

Targeted delivery of chemotherapy using HSP90 inhibitor drug conjugates is highly active against pancreatic cancer models.

Bobrov E, Skobeleva N, Restifo D, Beglyarova N, Cai KQ, Handorf E, Campbell K, Proia DA, Khazak V, Golemis EA, Astsaturov I.

Oncotarget. 2017 Jan 17;8(3):4399-4409. doi: 10.18632/oncotarget.12642.

25.

TumorNext: A comprehensive tumor profiling assay that incorporates high resolution copy number analysis and germline status to improve testing accuracy.

Gray PN, Vuong H, Tsai P, Lu HM, Mu W, Hsuan V, Hoo J, Shah S, Uyeda L, Fox S, Patel H, Janicek M, Brown S, Dobrea L, Wagman L, Plimack E, Mehra R, Golemis EA, Bilusic M, Zibelman M, Elliott A.

Oncotarget. 2016 Oct 18;7(42):68206-68228. doi: 10.18632/oncotarget.11910.

26.

EGFR and RB1 as Dual Biomarkers in HPV-Negative Head and Neck Cancer.

Beck TN, Georgopoulos R, Shagisultanova EI, Sarcu D, Handorf EA, Dubyk C, Lango MN, Ridge JA, Astsaturov I, Serebriiskii IG, Burtness BA, Mehra R, Golemis EA.

Mol Cancer Ther. 2016 Oct;15(10):2486-2497. Epub 2016 Aug 9.

27.

Anti-Müllerian Hormone Signaling Regulates Epithelial Plasticity and Chemoresistance in Lung Cancer.

Beck TN, Korobeynikov VA, Kudinov AE, Georgopoulos R, Solanki NR, Andrews-Hoke M, Kistner TM, Pépin D, Donahoe PK, Nicolas E, Einarson MB, Zhou Y, Boumber Y, Proia DA, Serebriiskii IG, Golemis EA.

Cell Rep. 2016 Jul 19;16(3):657-71. doi: 10.1016/j.celrep.2016.06.043. Epub 2016 Jul 7.

28.

Screening of Conditionally Reprogrammed Patient-Derived Carcinoma Cells Identifies ERCC3-MYC Interactions as a Target in Pancreatic Cancer.

Beglyarova N, Banina E, Zhou Y, Mukhamadeeva R, Andrianov G, Bobrov E, Lysenko E, Skobeleva N, Gabitova L, Restifo D, Pressman M, Serebriiskii IG, Hoffman JP, Paz K, Behrens D, Khazak V, Jablonski SA, Golemis EA, Weiner LM, Astsaturov I.

Clin Cancer Res. 2016 Dec 15;22(24):6153-6163. Epub 2016 Jul 6.

29.

POLD1: Central mediator of DNA replication and repair, and implication in cancer and other pathologies.

Nicolas E, Golemis EA, Arora S.

Gene. 2016 Sep 15;590(1):128-41. doi: 10.1016/j.gene.2016.06.031. Epub 2016 Jun 16. Review.

30.

Musashi-2 (MSI2) supports TGF-β signaling and inhibits claudins to promote non-small cell lung cancer (NSCLC) metastasis.

Kudinov AE, Deneka A, Nikonova AS, Beck TN, Ahn YH, Liu X, Martinez CF, Schultz FA, Reynolds S, Yang DH, Cai KQ, Yaghmour KM, Baker KA, Egleston BL, Nicolas E, Chikwem A, Andrianov G, Singh S, Borghaei H, Serebriiskii IG, Gibbons DL, Kurie JM, Golemis EA, Boumber Y.

Proc Natl Acad Sci U S A. 2016 Jun 21;113(25):6955-60. doi: 10.1073/pnas.1513616113. Epub 2016 Jun 6.

31.

A Novel HSP90 Inhibitor-Drug Conjugate to SN38 Is Highly Effective in Small Cell Lung Cancer.

Gaponova AV, Nikonova AS, Deneka A, Kopp MC, Kudinov AE, Skobeleva N, Khazak V, Ogawa LS, Cai KQ, Duncan KE, Duncan JS, Egleston BL, Proia DA, Boumber Y, Golemis EA.

Clin Cancer Res. 2016 Oct 15;22(20):5120-5129. doi: 10.1158/1078-0432.CCR-15-3068. Epub 2016 Jun 7.

33.

Genomic insights into head and neck cancer.

Beck TN, Golemis EA.

Cancers Head Neck. 2016;1. pii: 1. doi: 10.1186/s41199-016-0003-z. Epub 2016 Jun 3.

34.

A Synthetic Lethality Screen Using a Focused siRNA Library to Identify Sensitizers to Dasatinib Therapy for the Treatment of Epithelial Ovarian Cancer.

Pathak HB, Zhou Y, Sethi G, Hirst J, Schilder RJ, Golemis EA, Godwin AK.

PLoS One. 2015 Dec 4;10(12):e0144126. doi: 10.1371/journal.pone.0144126. eCollection 2015.

35.

Taking Snapshots of Ciliary Signaling.

Nikonova AS, Golemis EA.

Dev Cell. 2015 Nov 23;35(4):399-400. doi: 10.1016/j.devcel.2015.11.006.

36.

Opposing Effects of Inhibitors of Aurora-A and EGFR in Autosomal-Dominant Polycystic Kidney Disease.

Nikonova AS, Deneka AY, Eckman L, Kopp MC, Hensley HH, Egleston BL, Golemis EA.

Front Oncol. 2015 Oct 16;5:228. doi: 10.3389/fonc.2015.00228. eCollection 2015.

37.

Systematic evaluation of underlying defects in DNA repair as an approach to case-only assessment of familial prostate cancer.

Nicolas E, Arora S, Zhou Y, Serebriiskii IG, Andrake MD, Handorf ED, Bodian DL, Vockley JG, Dunbrack RL, Ross EA, Egleston BL, Hall MJ, Golemis EA, Giri VN, Daly MB.

Oncotarget. 2015 Nov 24;6(37):39614-33. doi: 10.18632/oncotarget.5554.

38.

Endogenous Sterol Metabolites Regulate Growth of EGFR/KRAS-Dependent Tumors via LXR.

Gabitova L, Restifo D, Gorin A, Manocha K, Handorf E, Yang DH, Cai KQ, Klein-Szanto AJ, Cunningham D, Kratz LE, Herman GE, Golemis EA, Astsaturov I.

Cell Rep. 2015 Sep 22;12(11):1927-38. doi: 10.1016/j.celrep.2015.08.023. Epub 2015 Sep 3.

39.

Genetic Variants That Predispose to DNA Double-Strand Breaks in Lymphocytes From a Subset of Patients With Familial Colorectal Carcinomas.

Arora S, Yan H, Cho I, Fan HY, Luo B, Gai X, Bodian DL, Vockley JG, Zhou Y, Handorf EA, Egleston BL, Andrake MD, Nicolas E, Serebriiskii IG, Yen TJ, Hall MJ, Golemis EA, Enders GH.

Gastroenterology. 2015 Dec;149(7):1872-1883.e9. doi: 10.1053/j.gastro.2015.08.052. Epub 2015 Sep 5.

40.

The tumor suppressor FBW7 controls ciliary length.

Nikonova AS, Golemis EA.

EMBO J. 2015 Oct 1;34(19):2388-90. doi: 10.15252/embj.201592588. Epub 2015 Aug 12. No abstract available.

41.

Phospho-T356RB1 predicts survival in HPV-negative squamous cell carcinoma of the head and neck.

Beck TN, Kaczmar J, Handorf E, Nikonova A, Dubyk C, Peri S, Lango M, Ridge JA, Serebriiskii IG, Burtness B, Golemis EA, Mehra R.

Oncotarget. 2015 Aug 7;6(22):18863-74.

42.

Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer.

Plimack ER, Dunbrack RL, Brennan TA, Andrake MD, Zhou Y, Serebriiskii IG, Slifker M, Alpaugh K, Dulaimi E, Palma N, Hoffman-Censits J, Bilusic M, Wong YN, Kutikov A, Viterbo R, Greenberg RE, Chen DY, Lallas CD, Trabulsi EJ, Yelensky R, McConkey DJ, Miller VA, Golemis EA, Ross EA.

Eur Urol. 2015 Dec;68(6):959-67. doi: 10.1016/j.eururo.2015.07.009. Epub 2015 Aug 1.

43.

Acquisition of estrogen independence induces TOB1-related mechanisms supporting breast cancer cell proliferation.

Zhang YW, Nasto RE, Varghese R, Jablonski SA, Serebriiskii IG, Surana R, Calvert VS, Bebu I, Murray J, Jin L, Johnson M, Riggins R, Ressom H, Petricoin E, Clarke R, Golemis EA, Weiner LM.

Oncogene. 2016 Mar 31;35(13):1643-56. doi: 10.1038/onc.2015.226. Epub 2015 Jul 13.

44.

Embryonal Fyn-associated substrate (EFS) and CASS4: The lesser-known CAS protein family members.

Deneka A, Korobeynikov V, Golemis EA.

Gene. 2015 Oct 1;570(1):25-35. doi: 10.1016/j.gene.2015.06.062. Epub 2015 Jun 26. Review.

45.

Compounds identified by virtual docking to a tetrameric EGFR extracellular domain can modulate Grb2 internalization.

Ramirez UD, Nikonova AS, Liu H, Pecherskaya A, Lawrence SH, Serebriiskii IG, Zhou Y, Robinson MK, Einarson MB, Golemis EA, Jaffe EK.

BMC Cancer. 2015 May 28;15:436. doi: 10.1186/s12885-015-1415-6.

46.

A new strategy to ERADicate HER2-positive breast tumors?

Arora S, Golemis EA.

Sci Signal. 2015 May 26;8(378):fs11. doi: 10.1126/scisignal.aac4746.

47.

Preclinical and clinical studies of the NEDD9 scaffold protein in cancer and other diseases.

Shagisultanova E, Gaponova AV, Gabbasov R, Nicolas E, Golemis EA.

Gene. 2015 Aug 1;567(1):1-11. doi: 10.1016/j.gene.2015.04.086. Epub 2015 May 9. Review.

48.

The hallmarks of cancer: relevance to the pathogenesis of polycystic kidney disease.

Seeger-Nukpezah T, Geynisman DM, Nikonova AS, Benzing T, Golemis EA.

Nat Rev Nephrol. 2015 Sep;11(9):515-34. doi: 10.1038/nrneph.2015.46. Epub 2015 Apr 14. Review.

49.

Control of ciliation in embryogenesis.

Nikonova AS, Golemis EA.

Nat Cell Biol. 2015 Feb;17(2):109-11. doi: 10.1038/ncb3103.

PMID:
25633272
50.

Adaptors for disorders of the brain? The cancer signaling proteins NEDD9, CASS4, and PTK2B in Alzheimer's disease.

Beck TN, Nicolas E, Kopp MC, Golemis EA.

Oncoscience. 2014 Jul 23;1(7):486-503. eCollection 2014.

Supplemental Content

Loading ...
Support Center